Soleno Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference
Soleno Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference
REDWOOD CITY, Calif., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that management will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Thursday, December 5, 2024, at 9:00 AM Eastern Time.
加州雷德伍德市，2024年11月27日(GLOBE NEWSWIRE) -- Soleno Therapeutics公司（"Soleno"）（納斯達克：SLNO），一家處於臨床階段的生物製藥公司，致力於開發治療罕見疾病的新型治療藥物，今天宣佈公司管理層將於2024年12月5日星期四美國東部時間上午9:00在派傑投資第36屆年度醫療保健大會上舉行圓桌討論。
A live audio webcast and replay of the fireside chat will be available in the Investors section on the Company's website at .
爐邊聊天的現場音頻網絡直播和重播將可在公司網站的投資者部分找到。
About Soleno Therapeutics, Inc.
Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. An NDA for its lead candidate, DCCR (diazoxide choline) extended-release tablets, a once-daily oral tablet for the treatment of Prader-Willi syndrome (PWS) is currently under review by the FDA and was granted Priority Review. For more information, please visit .
關於Soleno Therapeutics, Inc.
Soleno專注於開發和商業化罕見疾病的新型治療藥物。其首候選藥物DCCR（diazoxide choline）延時釋放片劑爲普拉德-威利綜合徵（PWS）的每日一次口服藥片目前正在FDA進行審查，並獲得了優先審查。更多信息，請訪問。
Corporate Contact:
Brian Ritchie
LifeSci Advisors, LLC
212-915-2578
公司聯繫人:
Brian Ritchie
LifeSci Advisors, LLC
212-915-2578
譯文內容由第三人軟體翻譯。
